2008
DOI: 10.1536/ihj.49.303
|View full text |Cite
|
Sign up to set email alerts
|

Short Term Fluvastatin Treatment Lowers Serum Asymmetric Dimethylarginine Levels in Patients With Metabolic Syndrome

Abstract: SUMMARYElevated concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, are associated with endothelial dysfunction. Metabolic syndrome (MetS) is also a condition associated with impaired endothelial function. To test the hypothesis that lipid lowering treatment with a statin lowers ADMA levels, we investigated the effect of fluvastatin treatment on serum ADMA levels in patients with MetS.A total of 85 hypercholesterolemic MetS patients (53 females, 32 males; mea… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

2009
2009
2017
2017

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(15 citation statements)
references
References 39 publications
0
15
0
Order By: Relevance
“…These experimental results suggest that statin therapy will decrease the level of ADMA. Almost all clinical studies (small sample size and shorter duration) showed no effect of statins on ADMA (positive effect only with 10 mg rosuvastatin and 80 mg fluvastatin) [29,30]. We believe that the difference between experimental and clinical studies is a result of low doses of simvastatin documented in the present study.…”
Section: Discussionmentioning
confidence: 57%
“…These experimental results suggest that statin therapy will decrease the level of ADMA. Almost all clinical studies (small sample size and shorter duration) showed no effect of statins on ADMA (positive effect only with 10 mg rosuvastatin and 80 mg fluvastatin) [29,30]. We believe that the difference between experimental and clinical studies is a result of low doses of simvastatin documented in the present study.…”
Section: Discussionmentioning
confidence: 57%
“…The decrease in ADMA values by EPA treatment was significant, but the decrease was approximately 6% and was small compared with that by other drugs, such as metformin (28%), 13 rosiglitazone (30%), 14 temocapril (10%), 18 telmisartan (12%), 20 rosuvastatin (18%), 23 and fluvastatin (25%). 24 Although this result may suggest that the effect of EPA is mild, there is a possibility that pioglitazone, ARB, and the statin that we had been using before EPA treatment reduced ADMA values and diminished the effect of EPA. Further, HbA1c levels in patients with DM were improved after the treatment.…”
Section: Discussionmentioning
confidence: 86%
“…In a breast cancer cell line (MCF-7), both simvastatin and fluvastatin inhibited Arg2 expression which was reversed with MA co-treatment[49]. Other mechanisms could involve inhibition of asymmetric dimethylarginine (ADMA)[50, 51] or modulation of transcription factors such as CCAAT/enhancer-binding protein (C/EBP) [5257]. …”
Section: Discussionmentioning
confidence: 99%